Novo Nordisk Faces Generic Competition for Weight-Loss Drugs

Despite a significant share price drop, Zealand Pharma's CEO remains optimistic, while Novo Nordisk anticipates competition from cheaper generic versions of its weight-loss drugs entering major markets this year.